What Analysts Are Saying About WAVE Life Sciences Stock
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for WAVE Life Sciences (NASDAQ:WVE) over the past three months, with a current average 12-month price target of $15.5, down from $17.00. The company faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a healthier debt-to-equity ratio.

June 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed ratings for WAVE Life Sciences, with a current average 12-month price target of $15.5, down from $17.00. The company faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a healthier debt-to-equity ratio.
The mixed analyst ratings and the downward revision of the average price target indicate uncertainty about the company's short-term performance. The financial challenges in revenue growth, net margin, ROE, and ROA are significant, but the healthier debt-to-equity ratio is a positive aspect. Overall, the impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100